論文・技術情報追加のお知らせ

1. A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database.

オマダサイクリンの副作用を解析、消化器症状や歯の変色を確認。

対象DB：FAERS

2. Pharmacovigilance analysis of the association between SGLT-2 inhibitors and diabetic foot infections using the FAERS database: An observational study.

カナグリフロジンと糖尿病性足感染症の強い関連をFAERSで示唆。

対象DB：FAERS

3. Characteristics of adverse events and clinical risks of intravenous immunoglobulin: a pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS).

静注用免疫グロブリンの安全性解析、溶血性貧血等の稀なシグナルを特定。

対象DB：FAERS

4. Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database.

免疫チェックポイント阻害薬による類天疱瘡のリスクと発現時期を解析。

対象DB：FAERS

5. Comparative safety profiles of spironolactone, eplerenone, and finerenone: a pharmacovigilance study based on FAERS data from 2004 to 2024.

3種のMRAの安全性比較、フィネレノンは性ホルモンへの影響が少。

対象DB：FAERS

6. Pharmacovigilance insights: safety profiles of antifungal agents for invasive aspergillosis.

アスペルギルス症治療薬の副作用を解析、薬剤間の特性差を評価。

対象DB：FAERS

7. Infection and infestation-related adverse events of ocrelizumab: A disproportionality analysis using FDA adverse event reporting system.

オクレリズマブによる感染症リスクを解析、呼吸器感染等が顕著。

対象DB：FAERS

8. Safety analysis of vinorelbine in the real world: a pharmacovigilance study based on the FAERS database.

ビノレルビンの副作用を解析、血液毒性や消化器症状などの頻度を確認。

対象DB：FAERS

9. Association between three lipid-lowering drugs and amnesia: a real-world pharmacovigilance study.

3種の脂質異常症治療薬と健忘症の関連を調査、有意なシグナルを検出。

対象DB：FAERS

10. Drug rash with eosinophilia and systemic symptoms: descriptive analysis of pharmacovigilance.

DRESS症候群の疑い例を解析、抗てんかん薬や抗菌薬が主要原因。

対象DB：FAERS

11. Musculoskeletal adverse events associated with bempedoic acid: a real-world pharmacovigilance study.

ベムペド酸による筋骨格系副作用を解析、痛風や筋痛リスクを特定。

対象DB：FAERS

12. Toward the future management of patients with CML and Ph + ALL: real-world safety insights from dasatinib pharmacovigilance.

ダサチニブの安全性を解析、胸水や肺高血圧症などのシグナルを検出。

対象DB：FAERS

13. Dipyridamole-associated pulmonary edema: discovery of a new potential adverse reaction signal based on the FAERS database.

ジピリダモールによる肺水腫の新規シグナルを検出し、臨床的注意を喚起。

対象DB：FAERS

14. Cardiac Adverse Events Associated with Dual Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis from the FDA Adverse Event Reporting System.

免疫チェックポイント阻害薬の併用療法による心毒性リスクを解析。

対象DB：FAERS

15. From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy.

非小細胞肺癌標的薬の副作用を解析、薬剤群別の特性をマップ化。

対象DB：FAERS

16. Mapping adverse events and monitoring priorities for trastuzumab deruxtecan use in metastatic breast cancer.

T-DXdの副作用を解析、間質性肺疾患等の監視の重要性を強調。

対象DB：FAERS

17. Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system.

プロテアソーム阻害薬による神経副作用を比較し、各薬の特性を解析。

対象DB：FAERS

18. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab.

ビメキズマブの副作用を解析、カンジダ症等の感染症リスクを確認。

対象DB：FAERS

19. Pharmacovigilance signal detection of psychiatric adverse events induced by third-generation antiepileptic drugs in children.

第3世代抗てんかん薬による精神副作用のシグナルを検出し比較。

対象DB：FAERS

20. A real-world signal detection analysis uncovering the safety profile of ketorolac tromethamine.

ケトララクの副作用を解析、腎不全や消化管出血のリスクを再確認。

対象DB：FAERS

21. Drug-induced urinary incontinence in pediatric patients: A disproportionality analysis of the FDA Adverse Event Reporting System.

小児の薬剤性尿失禁を解析、抗精神病薬や刺激薬との関連を特定。

対象DB：FAERS

22. Safety Surveillance for Hepatitis A Vaccine using the U.S. Vaccine Adverse Event Reporting System (VAERS) database.

A型肝炎ワクチンの安全性を解析、既存の知見と一致する結果。

対象DB：FAERS,VAERS

23. The safety of rituximab in pediatric nephrotic syndrome patients: a pharmacovigilance study of the FAERS database.

小児ネフローゼ症候群でのリツキシマブの安全性を解析し評価。

対象DB：FAERS

24. Spectrum mining of immune checkpoint inhibitor-related cutaneous toxicities and analysis of associated factors based on FAERS.

免疫チェックポイント阻害薬による皮膚毒性の種類と発現時期を解析。

対象DB：FAERS

25. Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS.

薬剤性進行性多巣性白質脳症の関連薬剤を特定しリスクを解析。

対象DB：FAERS

26. Unraveling Sex-Related Cardiovascular Toxicity of Immune Checkpoint Inhibitors by Pharmacovigilance and Single-Cell Transcriptomic Analysis.

免疫チェックポイント阻害薬の心毒性における男女差を大規模解析。

対象DB：FAERS

27. Thromboembolic events associated with antiangiogenic monoclonal antibodies: a disproportionality analysis from FDA adverse event reporting system (FAERS) database.

抗血管新生抗体薬による血栓塞栓症リスクを薬剤間で比較・解析。

対象DB：FAERS

28. Identification of novel signal of DRESS associated with antibiotics: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database.

抗菌薬によるDRESS症候群を解析、バンコマイシン等が強いシグナル。

対象DB：FAERS

29. Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS).

炎症性腸疾患治療におけるウステキヌマブの安全性を評価。

対象DB：FAERS

30. Sex differences in thyroid dysfunction onset timing induced by immune checkpoint inhibitors: JADER disproportionality analysis.

ICIによる甲状腺機能障害の発現時期に男女差があることをJADERで解明。

対象DB：JADER

31. Analysis of drug-drug interactions between psychiatric drugs in spontaneous adverse drug reaction reports from EudraVigilance.

精神科薬間の相互作用による副作用を解析、臨床的な注意点を提示。

対象DB：EudraVigilance

32. JAK Inhibitors and Memory Impairment: Disproportionality Analyses in the WHO Global Pharmacovigilance Database, VigiBase.

JAK阻害薬と記憶障害の関連を世界規模のデータベースで解析。

対象DB：VigiBase

33. Immune checkpoint inhibitor-induced pure red cell aplasia: a nationwide retrospective case series and literature review.

日本全国の調査でICIによる赤芽球癆の臨床的特徴と予後を解明。

対象DB：VigiBase

34. Home Medical Care and Reduced Risk of Rehospitalization After Aspiration Pneumonia in an Elderly Japanese Population: A Nationwide Inpatient Database Study.

誤嚥性肺炎後の在宅医療が再入院リスクを低減することを国内データで確認。

対象DB：DPC

35. Regional association between PM2.5 exposure and anti-VEGF treatment demand for age-related macular degeneration: a nationwide ecological study in Japan.

PM2.5曝露量と加齢黄斑変性の抗VEGF治療需要の相関を解析。

対象DB：NDB

36. Risk of Cancer Comparing Warfarin and Direct Oral Anticoagulants: Population-Based Cohort Studies in England and Hong Kong.

DOACとワーファリンの癌リスクを比較、薬剤間で有意な差は認めず。

対象DB：CPRD

37. Predicted Lean Body Mass and the Risk of Adverse Kidney Outcomes in Men.

筋肉量の指標が男性の腎予後悪化の独立した予測因子であることを解明。

対象DB：DeSC